Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
18 juin 2024 16h48 HE
|
Longeveron
Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
17 juin 2024 09h00 HE
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
17 juin 2024 08h38 HE
|
Longeveron
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
11 juin 2024 09h00 HE
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
10 juin 2024 09h00 HE
|
Longeveron
Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
03 juin 2024 09h00 HE
|
Longeveron
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
Longeveron® to Attend BIO International Convention 2024
28 mai 2024 08h05 HE
|
Longeveron
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Announces Board of Directors Planned Transitions
10 mai 2024 16h05 HE
|
Longeveron
Longeveron announces planned transitions on its Board of Directors.
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
02 mai 2024 08h03 HE
|
Longeveron
Longeveron to report Q1 2024 financial results on May 14, 2024.